Pacira BioSciences Rises 0.07% on Strong Earnings

On September 2, 2025, Pacira BioSciences saw a modest rise of 0.07% in pre-market trading, indicating a slight positive sentiment among investors.

Pacira BioSciences, Inc. is a company focused on developing and marketing non-opioid pain management and regenerative health solutions. Its flagship product, EXPAREL, provides postsurgical analgesia and reduces the consumption of opioid medications. The company's iovera system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature to targeted nerves, offering a non-pharmacological approach to pain management.

Recently, Pacira BioSciences reported strong second-quarter earnings, surpassing analysts' estimates. This positive financial performance has likely contributed to the recent market sentiment, as investors recognize the company's ability to deliver on its financial goals. The company's market capitalization stands at approximately $1.19 billion USD, reflecting its position as a mid-sized player in the pharmaceutical industry.

Analysts have rated Pacira BioSciences as a "Buy" with a 12-month target price of $29.00, indicating an 8.74% upside from the current price. This optimistic outlook is supported by the company's innovative product portfolio and its commitment to non-opioid pain management solutions, which are increasingly in demand as the healthcare industry seeks alternatives to opioid-based treatments.